Figure 1.

Impaired anti-tumor CD4⁺ T-cell priming in Atg5-deficient dendritic cells. (a) Experimental scheme for B. (b) Atg5^± or atg5^−/- chimera mice were inoculated subcutaneously with live EG7 cells on day 0. The mice were treated with systemic oxaliplatin on day 8. On day 13, CD4⁺ T cells and CD8⁺ T cells from draining lymph nodes were co-cultured with wild-type splenocytes as antigen-presenting cells in the presence or absence of SERPINB/OVA protein for 72 h. Concentrations of IFNG/IFN-γ in the culture medium were measured by ELISA. Mean concentrations are presented with standard deviations (ND: not detected; Student’s t-test, **P < 0.01). Data are representative of 3 independent experiments. (c) Experimental scheme for D. (d) CFSE-labeled OT-II CD4⁺ T cells were adoptively transferred into Atg5^+/- or atg5^−/- chimeras on day −1, and then apoptotic EG7 cells were injected into the footpads of mice on day 0. After 64 h, CFSE dilution was measured with flow cytometry. Data are representative of 2 independent experiments. (E) Atg5^f/f or ITGAX/CD11c-atg5^−/- mice were treated with systemic oxaliplatin 8 days after live EG7 subcutaneous inoculation. After 5 days of oxaliplatin treatment, CD4⁺ T cells from draining lymph nodes were co-cultured with wild-type splenocytes as antigen-presenting cells in the presence or absence of SERPINB/OVA protein for 72 h. Total amount of IFNG/IFN-γ in the culture supernatant was measured by ELISA. Mean concentrations are presented with SDs (Student’s t-test; ***P < 0.001). Data are representative of 3 independent experiments. (F) CFSE-labeled OT-II CD4⁺ T cells were adoptively transferred into Atg5^f/f or ITGAX/CD11c-atg5^−/- mice on day −1, and γ-ray–irradiated EG7 were then injected into the footpads of mice on day 0. CFSE dilution was measured by flow cytometry 64 h after irradiated EG7 injection. Data are representative of 3 independent experiments.